NICE's Casgevy recommendation (TA1044) carries a £300-600 million annual NHS exposure across just 200-300 eligible severe patients a year.

Sickle cell disease is the UK's largest haemoglobinopathy population and the largest in Europe: an estimated 15,000-17,000 patients, concentrated at specialist centres in London (Barts, King's, Imperial, Homerton, roughly 6,000 patients combined), Birmingham Heartlands (roughly 2,000), Manchester, Bristol, and Nottingham. The NHS has screened for SCD and sickle cell trait since 1999, so virtually all UK SCD patients are now diagnosed at birth; roughly 350-500 new SCD births occur annually, reflecting immigration patterns from Sub-Saharan Africa and the Caribbean.

Hydroxycarbamide is recommended for moderate-to-severe disease under the British Society for Haematology's 2018 guideline, generally three or more vaso-occlusive crises a year or significant organ damage. A 2022 NHS audit found roughly half of eligible UK patients on hydroxyurea, better than the US at 25-30% but below guideline target, with adherence, fertility concerns, and prescriber reluctance cited as barriers. Access changed in November 2023, when MHRA granted conditional approval to Casgevy, the first CRISPR gene therapy licensed in the UK for sickle cell disease. NICE's TA1044 recommends managed access for severe patients 12 and over who cannot access a matched-donor transplant, against a price exceeding £1.5 million and a £300-600 million annual NHS exposure.

One therapy, hydroxyurea, is about to be reshaped by a £300-600 million access decision.

Five questions this report answers:

Q1 - How is the UK's 15,000-17,000 SCD population distributed across specialist centres like Barts and Birmingham?

Q2 - Why does only half of hydroxyurea-eligible UK SCD patients actually receive it?

Q3 - What are the managed-access terms and budget impact of Casgevy's NICE recommendation (TA1044)?

Q4 - How many new SCD births does the UK see each year, and from where?

Q5 - Why does Lyfgenia remain unavailable to UK sickle cell patients despite US approval?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#SickleCellDisease #Casgevy #NICE #NHS #GeneTherapy #RareDisease

Live report page:  https://axlrx.ai/sickle-cell-disease/uk/disease-landscape/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                    hello@axlrx.ai

Web-                    https://axlrx.ai/